The combination of epirubicin plus docetaxel as neoadjuvant chemotherapy in locally-advanced breast cancer

Anticancer Research

Volumn 26, Issue 1 B, 2006, Pages 581-584

  Hirano, Akira ^a   Shimizu, Tadao ^a   Imamura, Hiroshi ^a   Watanabe, Osamu ^a   Kinoshita, Jun ^a   Okabe, Toshihiro ^a   Kimura, Kiyomi ^a   Kamimura, Mari ^a   Domoto, Kaoru ^a   Aiba, Motohiko ^a   Ogawa, Kenji ^a,b  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b NONE   (Japan)

Author keywords

Breast cancer; Docetaxel; Epirubicin; Neoadjuvant chemotherapy

Indexed keywords

DEXAMETHASONE; DOCETAXEL; EPIRUBICIN; FAMOTIDINE; GRANULOCYTE COLONY STIMULATING FACTOR; SEROTONIN 3 ANTAGONIST;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DIARRHEA; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HUMAN TISSUE; LEUKOPENIA; LIVER TOXICITY; LUNG TOXICITY; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY DYSFUNCTION; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; EPIRUBICIN; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; TAXOIDS;

EID: 32144435972     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352: 930-942, 1998.
2. Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, De Lena M, Tancini G, Bajetta E, Musumeci R and Veronesi U: Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294: 405-410, 1976.
3. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz AB Jr, Hoehn JL, Lees AW, Dimitrov NV and Bear HD: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672-2685, 1998.
4. Belembaogo E, Feillel V, Chollet P, Cure H, Verrelle P, Kwiatkowski F, Achard JL, Le Bouedec G, Chassagne J and Bignon YJ: Neoadjuvant chemotherapy in 126 operable breast cancers. Eur J Cancer 28A: 896-900, 1992.
5. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vanderveiden C, Duchateau L and Cooperating investigators: Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19: 4224-4237, 2001.
6. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN and Singletary SE: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17: 460-469, 1999.
7. Fumoleau P, Chevallier B, Kerbrat P, Krakowski Y, Misset JL, Maugard-Louboutin C, Dieras V, Azli N, Bougon N, Riva A and Roche H: A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC. Ann Oncol 7: 165-171, 1996.
8. Amat S, Bougnoux P, Penault-Llorca F, Fetissof F, Cure H, Kwiatkowski F, Achard JL, Body G, Dauplat J and Chollet P: Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate. Br J Cancer 88: 1339-45, 2003.
9. Sjostrom J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson-Lonn S, Bengtsson NO, Ostenstad B, Mjaaland I, Palm-Sjovall M, Wist E, Valvere V, Anderson H and Bergh J: Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 35: 1194-201, 1999.
10. Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschenes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Molino A, Nortier JW, Richel DJ, Nagykalnai T, Siedlecki P, Wilking N, Genot JY, Hupperets PS, Pannuti F, Skarlos D, Tomiak EM, Murawsky M, Alakl M and Aapro M: Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 17: 1413-1424, 1999.
11. Bonneterre J, Dieras V, Tubiana-Hulin M, Bougnoux P, Bonneterre ME, Delozier T, Mayer F, Culine S, Dohoulou N and Bendahmane B: Phase II multicentre randomised study of docetaxel plus epirubicin vs. 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer. Br J Cancer 91: 1466-1471, 2004.
12. Bear H, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL and Wolmark N: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21: 4165-4174, 2003.
13. Ganem G, Tubiana-Hulin M, Fumoleau P, Combe M, Misset JL, Vannetzel JM, Bachelot T, De Ybarlucea LR, Lotz V, Bendahmane B and Dieras V: Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer. Ann Oncol 14: 1623-1628, 2003.
14. de Matteis A, Nuzzo F, D'Aiuto G, Labonia V, Landi G, Rossi E, Mastro AA, Botti G, De Maio E and Perrone F: Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast: a single-center, phase II study. Cancer 94: 895-901, 2002.
15. Wittekind CH: Breast Tumours. In: TNM Classification of Malignant Tumours Sixth ed., Wiley-Liss, New York, USA, pp. 131-141, 2002.
16. Kurosumi M, Akiyama F, Iwase T, Motomura K, Okazaki M and Tsuda H: Histopathological criteria for assessment of therapeutic response in breast cancer. Breast Cancer 1: 1-2, 2001.
17. National Cancer Institute: Common Treatment Criterion for Adverse Event Version 3.0. Dec.12, 2003. http://ctep.info.nih.gov/ reporting/ctcnew.html
18. Matsuo K, Fukutomi T, Watanabe T, Hasegawa T, Tsuda H and Akashi-Tanaka S: Concordance in pathological responses to neoadjuvant chemotherapy between invasive and noninvasive components of primary breast carcinomas. Breast Cancer 9: 75-81, 2002.
19. Pagani O, Sessa C, Martinelli G, Crivellari D, Buonadonna A, Thurlimann B, Hess D, Borner M, Bauer J, Zampino G, Zimatore M, Graffeo R, Riva A and Goldhirsch A: Dose-finding study of epirubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer. Ann Oncol 10: 539-545, 1999.
20. Adachi I, Watanabe T, Takashima S, Narabayashi M, Horikoshi N, Aoyama H and Taguchi T: A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer. Br J Cancer 73: 210-216, 1996.
21. Jackisch C, von Minckwitz G, Raab G, Schuette M, Blohmer JU, Hilfrich J, Gerber B, Costa S, Merkle E, Eidtmann H, Lampe D, DuBois A, Tulusan AH, Caputo A and Kaufmann M: Primary endpoint analysis of the Geparduo-study-preoperative chemotherapy (PCT) comparing dose-dense versus sequential adriamycin/docetaxel combination in operable breast cancer (T2-3, NO-2, M0). San Antonio Breast Cancer Symposium 2002. Abst #152.
22. Jackisch C, von Minckwitz G, Eidtmann H, Costa SD, Raab G, Blohmer JU, Schutte M, Gerber B, Merkle E, Gademann G, Lampe D, Hilfrich J, Tulusan AH, Caputo A and Kaufmann M: Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysis. Clin Breast Caner 3: 276-280, 2002.
23. Bear HD, Anderson S, Smith RE, Robidoux A, Kahlenberg MS, Margolese RG, Dakhil SR, Pajon ER, Hoehn JL, Mamounas EP, Geyer CE, Julian TB and Wolmark N: A randomized trial comparing preoperative (preop) doxorubicin/cyclophosphamide (AC) to preop AC followed by preop docetaxel (T) and to preop AC followed by postoperative (postop) T in patients with operable carcinoma of the breast: results of NSABP B-27. San Antonio Breast Cancer Symposium 2004. Abst #26.